Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan's business focuses on neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease; autoimmune diseases, including MS and Crohn's disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn's disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.
Lower Grand Canal Street, Dublin 2
DUBLIN, Ireland 2
|Chief Executive Officer, Executive Director||G. Kelly Martin|
|Chief Financial Officer, Executive Vice President||Nigel Clerkin|
|Chief Operating Officer||Hans Hasler|
|Executive Vice President, Company Secretary||William Daniel|
|Senior Vice President, Chief Compliance Officer||Fabiana Lacerca-Allen|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||510.3M||Book Value||$1.04|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||29,186.8|
|Ex-Div Date||12/21/12||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-231,850.00%|
*GAAP = prior to non-GAAP analyst adjusted earnings.